December 22, 2008
KALOBIOS RAISES ADDITIONAL $12 MILLION IN SERIES D VENTURE FINANCING FOR A NEW TOTAL OF $32 MILLION

December 15, 2008
ENTREMED FOCUSES ON DEVELOPMENT OF ENMD-2076

December 11, 2008
SYNOSIA INITIATES PROOF-OF-CONCEPT TRIAL OF NITISINONE

December 9, 2008
ENTREMED INITIATES ENMD-2076 CLINICAL TRIAL IN MULTIPLE MYELOMA

December 8, 2008
AFFYMETRIX COMPLETES ACQUISITION OF PANOMICS

November 13, 2008
CLINICAL DATA SHOW LONG-ACTING HUMAN GROWTH HORMONE ARX201 IS SAFE AND WELL TOLERATED

November 12, 2008
ENTREMED REPORTS CLINICAL PROGRAM PROGRESS AND COMPANY UPDATE

November 11, 2008
AFFYMETRIX TO ACQUIRE PANOMICS

November 10, 2008
ENTREMED'S MKC-1 MEETS PRIMARY EFFICACY ENDPOINT IN NON-SMALL CELL LUNG CANCER CLINICAL TRIAL

November 6, 2008
ENTREMED REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS

November 5, 2008
AMBRX, INC. TO PRESENT PHASE I/II CLINICAL DATA FOR OPTIMIZED, LONG ACTING HUMAN GROWTH HORMONE ANALOGUE

November 3, 2008
SYNOSIA THERAPEUTICS STARTS PHASE IIA TRIAL OF NEPICASTAT FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER (PTSD)

September 23, 2008
KALOBIOS RAISES $20 MILLION IN SERIES D VENTURE FINANCING

September 18, 2008
PULMATRIX APPOINTS JOHN P. HANRAHAN CHIEF MEDICAL OFFICER

September 3, 2008
SYNOSIA THERAPEUTICS ANNOUNCES APPOINTMENT OF VICE PRESIDENT OF NEUROPHARMACOLOGY

September 2, 2008
IKARIA® ACQUIRES NORTH AMERICAN RIGHTS TO LUCASSIN® FROM ORPHAN THERAPEUTICS

July 30, 2008
SYNOSIA THERAPEUTICS INITIATES STUDY OF POTENTIAL FIRST DRUG THERAPY FOR COCAINE DEPENDENCE

July 24, 2008
US DEPARTMENT OF DEFENSE TO FUND TRIAL USING NOVEL COMPOUND FROM SYNOSIA THERAPEUTICS

July 21, 2008
IKARIA'S INOFLO (NITRIC OXIDE) FOR INHALATION APPROVED IN JAPAN

July 2, 2008
PEARL THERAPEUTICS CLOSES $18 MILLION FINANCING

June 23, 2008
RELYPSA - 2008 FIERCE 15

June 18, 2008
IKARIA'S INOFLO (NITRIC OXIDE) FOR INHALATION TO BE OFFICIALLY APPROVED IN JAPAN

June 10, 2008
SYNOSIA BEGINS PROOF-OF-MECHANISM TRIAL FOR NITISINONE

June 3, 2008
ENTREMED PRESENTS MCK-1 PHASE 2 DATA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

May 19, 2008
IKARIA COMPLETES DOSING OF PHASE 1A CLINICAL STUDY FOR IK-1001 (SODIUM SULFIDE) FOR INJECTION

May 8, 2008
DANA-FARBER CANCER INSTITUTE COMMENCES PHASE 1 TRIAL WITH ENTREMED'S SELECTIVE KINASE INHIBITOR

April 28, 2008
KALOBIOS COMPLETES PATIENT DOSING IN ITS U.S. PHASE 1 TRIAL OF ITS THIRD DRUG CANDIDATE, KB003

April 15, 2008
ANAPHORE, INC. RECEIVES $8M FINANCING

April 9, 2008
ENTREMED ACHIEVES A KEY MILESTONE THROUGH INITIATION OF ENMD-2076 CLINICAL PROGRAM

April 2, 2008
ENTREMED COMMENCES CONTINUOUS DOSING CLINICAL TRIAL FOR MKC-1

March 31, 2008
KALOBIOS INITIATES PHASE 1/2 TRIAL OF HUMANEERED(TM) MONOCLONAL ANTIBODY KB001 FOR TREATMENT OF PSEUDOMONAS INFECTIONS IN CYCTIC FIBROSIS PATIENTS

March 31, 2008
SYNOSIA STARTS PHASE II EFFICACY TRIAL FOR RUFINAMIDE

March 10, 2008
KALOBIOS INITIATES PHASE 1/2 TRIAL OF KBOO2 ENGINEERED MONOCLONAL ANTIBODY IN PERSISTENT ASTHMA

March 6, 2008
MARCADIA BIOTECH, INC. AND MERCK & CO., INC. ENTER STRATEGIC COLLABORATION

February 28, 2008
PHASERX ANNOUNCES SEED FINANCING

February 26, 2008
AMBRX APPOINTS DOUGLAS AXELROD SENIOR VICE PRESIDENT FOR CLINICAL RESEARCH AND DEVELOPMENT

February 20, 2008
5AM VENTURES ANNOUNCES EXPANSION OF INVESTMENT TEAM: NAMES RICHARD ULEVITCH VENTURE PARTNER; PROMOTES KEVIN FORREST AND ANDREW MCMILLAN TO PRINCIPAL

February 4, 2008
SYNOSIA THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER TO NEW COMPANY HEADQUARTERS IN SWITZERLAND

January 29, 2008
CHEMDIV, INC. AND ACHAOGEN ENTER INTO A DISCOVERY COLLABORATION

January 29, 2008
KALOBIOS STRENGHTENS DEVELOPMENT EXPERTISE WITH ADDITIONS TO SENIOR MANAGEMENT TEAM

January 28, 2008
KALOBIOS ELECTS DENISE M. GILBERT, PH.D. TO THE BOARD OF DIRECTORS

January 23, 2008
ENTREMED COMMENCES PHASE 2 STUDY WITH MKC-1 IN OVARIAN/ENDOMETRIAL CANCERS

January 22, 2008
ROBERT CONNELLY JOINS PULMATRIX AS CEO

January 22, 2008
SYNOSIA ANNOUNCES ENCOURAGING RESULTS OF PROOF-OF-CONCEPT CLINICAL TRIAL FOR EPILEPSY DRUG RUFINAMIDE AS A TREATMENT FOR MOOD DISORDERS

January 9, 2008
IKARIA APPOINTS DANIEL TASSE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER